Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis.

Journal of hepatology - 1 Feb 2015

Londoño Maria-Carlota, Perelló Christie, Cabezas Joaquín, Cañete Nuria, Lens Sabela, Mariño Zoe, Gambato Martina, Rodríguez Raquel, Menéndez Susana, Carrión José A, Crespo Javier, Calleja José Luis, Forns Xavier

Abstract excerpt

BACKGROUND & AIMS: Antiviral therapy with interferon and ribavirin (double therapy) is associated with a significant risk of developing bacterial infections in patients with hepatitis C-related cirrhosis. The addition of telaprevir or boceprevir seems to increase this risk but there are no studies yet to compare the infection rate between both treatments. We aimed to assess rate, type and predictive factors of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Bacterial Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Incidence

Share to Liver Cirrhosis

Share to Protease Inhibitors

Source

Identifiers

PMID: 25281861
DOI: 10.1016/j.jhep.2014.09.025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis.PMID 25281861Read ↗

Protease inhibitor-based triple therapy in chronic hepatitis C: guidelines by the French Association for the Study of the Liver.Semantic proximity Read ↗

Effectiveness and safety of first-generation protease inhibitors in real-world patients with hepatitis C virus genotype 1 infection in Brazil: a multicenter study.Semantic proximity Read ↗

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care.Semantic proximity Read ↗

Risk of hepatitis B virus reactivation in hepatitis B virus + hepatitis C virus-co-infected patients with compensated liver cirrhosis treated with ombitasvir, paritaprevir/r + dasabuvir + ribavirin.Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.Semantic proximity Read ↗

How to optimize HCV therapy in genotype 1 patients with cirrhosis.Semantic proximity Read ↗

Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosis.Semantic proximity Read ↗

Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.Semantic proximity Read ↗

Impact of Telaprevir in HCV Patients with Cirrhosis and RVR: Real-Life Data from Boceprevir or Telaprevir based "Triple Therapy" Experience in Southern Italy.Semantic proximity Read ↗

Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.Semantic proximity Read ↗

Impact of Different Sources of Infection on Therapy Response in Chronic Hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.